ALISO VIEJO, Calif. — Ambry Genetics said its CARE Program has won the 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution.”
Ambry, a clinical genomic testing company and wholly owned subsidiary of Tempus AI Inc., said the award recognizes the CARE Program’s role in helping health systems identify patients at increased risk for breast cancer or those who otherwise qualify for hereditary cancer testing.
The MedTech Breakthrough Awards recognize companies and products in digital health and medical technology. Ambry said CARE was selected from more than 5,000 nominations worldwide.
CARE, which stands for Comprehensive, Assessment, Risk, and Education, is an EHR-integrated digital risk assessment program. The platform is designed to fit into existing clinical workflows, identify at-risk patients, provide personalized education and streamline the genetic test ordering and results process for providers.
Ambry said the program gives clinicians information about a patient’s risk before a visit, supporting more personalized care and earlier cancer detection through advanced screening. The program also connects patients with certified genetic counselors, creating an end-to-end model for genetic care.
“CARE has fundamentally changed how we care for patients at risk,” said Kevin M. Banks, Ph.D., Executive Director of Precision Health at The Christ Hospital Health Network. “It simplifies what used to be a ‘process’ by seamlessly integrating patient education and gives our clinicians critical insights when they matter most. CARE has not only smoothed our workflows but has also made a real difference in determining patient care.”
“Receiving this award alongside other industry leaders highlights the importance of integrating genetic insights directly into everyday clinical care to improve outcomes for high-risk patients,” said Tom Schoenherr, CEO of Diagnostics at Tempus. “CARE exemplifies Ambry’s commitment to streamlining clinical workflows and enabling providers to deliver more proactive, personalized care. We are incredibly proud of the impact CARE has already made, and will continue to make, in advancing care for high-risk patients.”
